VR Logo

Eloxx Pharmaceuticals Inc. (ELOX) download report


Healthcare | Biotechnology & Pharma Research

Eloxx Pharmaceuticals Inc. (ELOX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases.

IPO Date: 19-Jan-2018

Pres, CEO & Director: Mr. Sumit Aggarwal M.B.A.

Interim CFO, Principal Financial Officer & Principal Accounting Officer: Mr. Daniel E. Geffken M.B.A., MBA

Listing: NASDAQ: ELOX

Country: United States

Headquarters: Watertown, MA

Website: https://www.eloxxpharma.com

Key Facts

Market cap: $25.55 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-69.65 Mln

Cash: $39.77 Mln

Total Debt: $13.41 Mln

Insider's Holding: 12.23%

Liquidity: Low

52 Week range: $0.21 - 1.89

Shares outstanding: 86,653,104

10 Years Aggregate:

  • CFO: $-176.03 Mln
  • EBITDA: $-248.93 Mln
  • Net Profit: $-277.22 Mln

Stock Performance

Time Period Eloxx Pharmaceuticals (ELOX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-58.260.41-11.58
1 month17.787.968.86
3 months-11.506.67-2.19
1 Year-77.327.77-6.23
3 Years-66.1816.829.73
5 Years-44.1012.637.72
10 Years-53.3012.7610.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year Eloxx Pharmaceuticals (ELOX) S&P Small-Cap 600 S&P BSE Sensex
2021-82.2625.2721.99
2020-45.929.5715.75
2019-38.7220.8614.38
201849.79-9.705.87
2017185.3111.7327.91
2016-64.8624.741.95
2015-51.34-3.36-5.03